BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cadonilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cadonilimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06341335-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT06341335)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Study of AK104/Placebo Plus AK
 109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenoca
 rcinoma\nEstimated primary completion: November 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06341335
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984718-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06984718)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Sec
 ond-line HCC\nEstimated primary completion: 30 November 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06984718
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586904-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 1 readout est. (NCT07586904)
DESCRIPTION:Cadonilimab\, phase 1.\nStudy: Efficacy and Safety of Neoadjuva
 nt Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage I
 II/IV Melanoma.\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07586904
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04556253-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT04556253)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Perioperative Cadonilimab (AK104
 ) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and 
 Colorectal Adenocarcinoma\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04556253
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221748-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2/3 readout est. (NCT06221748)
DESCRIPTION:Cadonilimab\, phase 2/3.\nStudy: DV Combined With Cadonilimab i
 n Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Juncti
 on Adenocarcinoma After Progression on First-line Therapy\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06221748
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05926700-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT05926700)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Efficacy and Safety of Cadonilim
 ab Plus Anlotinib in Advanced STS That Failed the Previous First-line Stan
 dard Treatment\nEstimated primary completion: 1 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05926700
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646055-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT06646055)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: AK112 and Cadonilimab Combined
  With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06646055
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467500-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06467500)
DESCRIPTION:Cadonilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 rospective\, Open-label\, Single-center\, Single-arm Phase II Clinical Stu
 dy of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patien
 ts With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and
  Failed Immunotherapy\nEstimated primary completion: 30 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06467500
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551207-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cadonilimab: Phase na readout est. (NCT06551207)
DESCRIPTION:Cadonilimab\, phase na.\nStudy: Cadonilimab Combined With Fruqu
 intinib and SBRT as Athird-line and Posterior Line Treatment in Patients W
 ith MSS CRC\nEstimated primary completion: 30 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06551207
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06477523-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT06477523)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: Phase 1b/2 Study of LDRT in Co
 mbination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
 \nEstimated primary completion: 31 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06477523
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05944224-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT05944224)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: A Study to Efficacy and Safety
  of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients Wit
 h Advanced Solid Tumors.\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05944224
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05747716-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT05747716)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: SBRT Combined With Fruquintinib 
 Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05747716
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769971-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06769971)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Phase II Study of Ivonescimab an
 d Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06769971
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104149-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07104149)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: Neoadjuvant Ch
 emotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07104149
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243951-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07243951)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Phase
  II Clinical Study on the Efficacy and Safety of the Combination of Cadoni
 limab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Car
 cinoma and Intrahepatic Cholangiocarcinoma\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cad
 onilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07243951
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06196697-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06196697)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: AK104 in Combination With AK112 
 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Ca
 ncer\nEstimated primary completion: January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06196697
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519591-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06519591)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Systemic Application of Cadonili
 mab\, LM-302\, and S-1 Combined With Intraperitoneal Infusion of Paclitaxe
 l for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritonea
 l Metastasis\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06519591
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06367075-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06367075)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: A Trial of Cadonilimab With Adri
 amycin in Patients With Advanced Soft Tissue Sarcoma\nEstimated primary co
 mpletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06367075
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142423-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT05142423)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: A Study of AK109 Combined With
  AK104 in Patients With Advanced Solid Tumors\nEstimated primary completio
 n: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cadoni
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05142423
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05794750-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT05794750)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Assess the Efficacy of Radiother
 apy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC
 （AK104-IIT-13）\nEstimated primary completion: 24 April 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05794750
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06349967-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06349967)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Nab-paclitaxel Combined With Cad
 onilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer\
 nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06349967
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003022-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07003022)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Phase Ⅱ Clinical Trial of Cado
 nilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC\
 nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07003022
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052253-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07052253)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet fo
 r Advanced HCC.\nEstimated primary completion: 10 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07052253
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356688-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06356688)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: A Clinical Study on the Efficacy
  and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With C
 adonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamo
 us Cell Carcinoma\nEstimated primary completion: 1 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06356688
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416930-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06416930)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Study of Cadonilimab Combined Wi
 th Chemotherapy in Recurrent / Refractory Pleural Mesothelioma\nEstimated 
 primary completion: 20 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06416930
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635290-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07635290)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Anlotinib+Cadonilimab+PULSAR in 
 Advanced Biliary Tract Cancer\nEstimated primary completion: 30 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07635290
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07909265-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07909265)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Prospective Study of Cadonilimab
  With Lenvatinib in Renal Cell Carcinoma\nEstimated primary completion: 1 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cadonilima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 909265
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05587374-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT05587374)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Cadonilimab (PD-1/CTLA-4 Bispeci
 fic Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
 \nEstimated primary completion: 1 August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05587374
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577961-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT06577961)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: Vorolanib Combined With Cadoni
 limab in the Treatment of Untreated Advanced RCC Patients\nEstimated prima
 ry completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06577961
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06542549-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT06542549)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Efficacy and Safety of AK104 Com
 bined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Canc
 er\nEstimated primary completion: 31 October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06542549
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06702826-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06702826)
DESCRIPTION:Cadonilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cad
 onilimab Combined With Stereotactic Radiotherapy as Second-line Treatment 
 for Brain Metastases\nEstimated primary completion: 1 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06702826
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449780-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271117
DTEND;VALUE=DATE:20271118
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07449780)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Study of AK104 (SC) in Combina
 tion With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combin
 ation With XELOX in Participants With Unresectable Locally Advanced or Met
 astatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
 \nEstimated primary completion: 17 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07449780
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940921-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT06940921)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: SBRT-LDRT-Cadonilimab for Adva
 nced Gastric\, Colorectal and Ovarian Cancers With Peritoneal Metastases\n
 Estimated primary completion: 30 November 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06940921
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245446-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07245446)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: A Study of Ivonescimab in First-
 Line ES-SCLC\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07245446
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05941741-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT05941741)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: IC Plus Low-dose Radiation Plus 
 Cadonilimab in LANPC\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05941741
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544784-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07544784)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: AK104 Plus Radiotherapy Combined
  With Standard Therapy Versus Standard Therapy as First-Line Treatment for
  pMMR/MSS CRLM (APSOC)\nEstimated primary completion: 1 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07544784
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762080-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT06762080)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: Intrathecal Combination of Pro
 grammed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4
 ) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis\nEstima
 ted primary completion: 30 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06762080
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424626-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 1 readout est. (NCT06424626)
DESCRIPTION:Cadonilimab\, phase 1.\nStudy: A Trial of AK104 or AK112 in Com
 bination With Axitinib in Patients With Metastatic Mucosal Melanoma\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06424626
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06681285-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06681285)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Cadonilimab Combined With Anloti
 nib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamou
 s Cell Carcinoma (CAR-RMEC)\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06681285
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998394-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06998394)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: A Single-Arm\,
  Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in
  Oligometastatic Stage IVB Cervical Cancer\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cad
 onilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06998394
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06913218-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:Cadonilimab: Phase 1 readout est. (NCT06913218)
DESCRIPTION:Cadonilimab\, phase 1.\nStudy: A Study of mRNA Vaccines AK154 M
 onotherapy or in Combination With AK104/AK112\,and Sequential mFOLFIRINOX 
 in Surgically Resected PDAC\nEstimated primary completion: 23 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06913218
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908147-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cadonilimab: Phase 1 readout est. (NCT07908147)
DESCRIPTION:Cadonilimab\, phase 1.\nStudy: Biomarker-guided RAdiation-defer
 ring Treatment in Younger GBM Patients - Pilot Study\nEstimated primary co
 mpletion: March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cadonilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07908147
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929663-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cadonilimab: Phase 1 readout est. (NCT06929663)
DESCRIPTION:Cadonilimab\, phase 1.\nStudy: A Study of AK146D1 as Monotherap
 y and in Combination With AK104 or AK112\, in the Treatment of Advanced So
 lid Tumors\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06929663
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Precision Treatment of Recurrent
 /Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstimated
  primary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400536-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20280718
DTEND;VALUE=DATE:20280719
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07400536)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Clinical Study on the Treatmen
 t of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT\nEs
 timated primary completion: 18 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07400536
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540729-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06540729)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: RC48 in Combination With AK104 a
 nd Bevacizumab in OCCC\nEstimated primary completion: 1 August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06540729
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878196-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cadonilimab: Phase na readout est. (NCT06878196)
DESCRIPTION:Cadonilimab\, phase na\, Cervical Cancer.\nStudy: ctDNA-guided 
 First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervic
 al Cancer\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06878196
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649174-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07649174)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: Cadonilimab Pl
 us Chemotherapy in LACC: A Prospective\, Multicenter\, Randomized Phase II
  Trial\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07649174
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832917-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT06832917)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Short-course Radiation (SCRT) Fo
 llowed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for
  Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter\, Two-
 arm Parallel\, Open-label\, Randomised Phase III Trial (NeoCaCRT-III)\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06832917
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06949033-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT06949033)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Neoadjuvant Cadonilimab Combined
  With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Local
 ly Advanced Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06949033
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450963-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07450963)
DESCRIPTION:Cadonilimab\, phase 2\, Cervical Cancer.\nStudy: Cadonilimab Co
 mbined With RT in LACC Patients Ineligible for CCRT\nEstimated primary com
 pletion: February 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07450963
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877194-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07877194)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: A Clinical Study of Ivonescimab 
 in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer\nE
 stimated primary completion: 12 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07877194
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631000-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290527
DTEND;VALUE=DATE:20290528
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07631000)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: A Study of Cadonilimab Combined 
 With Chemotherapy in People With Gastric or Gastroesophageal Junction Canc
 er\nEstimated primary completion: 27 May 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07631000
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789848-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06789848)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Liguf
 alimab and Cadonilimab in Advanced Liver Cancers\nEstimated primary comple
 tion: 31 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 donilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06789848
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023315-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07023315)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Phase III Clinical Study of Ca
 donilimab Plus SOX as Perioperative Treatment for Patients With Resectable
  G/GEJ Adenocarcinoma\nEstimated primary completion: July 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07023315
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700979-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290818
DTEND;VALUE=DATE:20290819
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07700979)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Phase 3 Study of Cadonilimab Com
 bined With Chemotherapy vs Chemotherapy in Combination With or Without Niv
 olumab for the 1L Treatment of Participants With HER2-negative\, Previousl
 y Untreated\, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma\nEstim
 ated primary completion: 18 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07700979
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446257-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Cadonilimab: Phase 1 readout est. (NCT07446257)
DESCRIPTION:Cadonilimab\, phase 1\, Hepatocellular Carcinoma.\nStudy: THIO 
 and Cadonilimab in Resectable Hepatocellular Carcinoma\nEstimated primary 
 completion: 1 September 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07446257
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263919-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07263919)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Perioperative Cadonilimab Combin
 ed With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Ca
 rcinoma (ESCC)\nEstimated primary completion: March 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07263919
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412613-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20300615
DTEND;VALUE=DATE:20300616
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07412613)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Neoadjuvant/Adjuvant AK104 in Mi
 crosatellite Instability-high or Mismatch Repair-deficient\, Resectable Co
 lon Cancer\nEstimated primary completion: 15 June 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07412613
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815834-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07815834)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: FAPI-Guided Radiotherapy With Ca
 donilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: 
 A Phase III Randomized Controlled Trial (TORHC-PM02)\nEstimated primary co
 mpletion: 1 August 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cadonilimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07815834
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946836-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20310501
DTEND;VALUE=DATE:20310502
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06946836)
DESCRIPTION:Cadonilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Com
 parison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 
 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 
 Expression: A Single-Center\, Randomized\, Exploratory Clinical Study\nEst
 imated primary completion: 1 May 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06946836
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900256-1994@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20330401
DTEND;VALUE=DATE:20330402
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07900256)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: A Preliminary Exploratory Study 
 of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in 
 Early Endometrial Cancer\nEstimated primary completion: 1 April 2033. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07900256
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
